Oncopeptides AB (publ) (ONCO.ST)
SEK 1.95
(-0.2%)
SEK 1.95
(-0.2%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 2.42 Million SEK | 0.0% |
| 2022 | - SEK | -100.0% |
| 2021 | 1.00 SEK | -100.0% |
| 2020 | 8.66 Million SEK | 0.0% |
| 2019 | - SEK | 100.0% |
| 2018 | -2.45 Million SEK | -103.41% |
| 2017 | 71.98 Million SEK | 2529.77% |
| 2016 | -2.96 Million SEK | 0.0% |
| 2015 | - SEK | -100.0% |
| 2014 | 1.00 SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 4.79 Million SEK | -3.91% |
| 2024 Q1 | 4.98 Million SEK | 105.57% |
| 2023 Q2 | 2 Million SEK | 93.61% |
| 2023 Q3 | 1.92 Million SEK | -3.8% |
| 2023 Q4 | 2.42 Million SEK | 26.04% |
| 2023 Q1 | 1.03 Million SEK | 0.0% |
| 2023 FY | 2.42 Million SEK | 0.0% |
| 2022 Q3 | -27.51 Million SEK | 13.3% |
| 2022 Q1 | -36.89 Million SEK | -3689000100.0% |
| 2022 Q2 | -31.73 Million SEK | 13.97% |
| 2022 FY | - SEK | -100.0% |
| 2022 Q4 | - SEK | 100.0% |
| 2021 FY | 1.00 SEK | -100.0% |
| 2021 Q4 | 1.00 SEK | -100.0% |
| 2021 Q3 | 25.45 Million SEK | 14.58% |
| 2021 Q2 | 22.21 Million SEK | 91.02% |
| 2021 Q1 | 11.62 Million SEK | 34.21% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q4 | 8.66 Million SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 FY | 8.66 Million SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 FY | - SEK | 100.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 FY | -2.45 Million SEK | -103.41% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 FY | 71.98 Million SEK | 2529.77% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | -2.96 Million SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | -100.0% |
| 2014 FY | 1.00 SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alzinova AB (publ) | -3.27 Million SEK | 173.978% |
| Amniotics AB (publ) | 534 Thousand SEK | -354.12% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 88.129% |
| Genovis AB (publ.) | 14.9 Million SEK | 83.73% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 93.116% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 380.997% |
| Saniona AB (publ) | 1.00 SEK | -242499900.0% |
| Simris Alg AB (publ) | 1.09 Million SEK | -122.273% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | 2.08 Million SEK | -16.587% |
| Active Biotech AB (publ) | -2500.00 SEK | 97100.0% |
| Camurus AB (publ) | 100.95 Million SEK | 97.598% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 39.886% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 163289.771% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 124458.974% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 249.139% |
| NextCell Pharma AB | 545.23 Thousand SEK | -344.761% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 97.731% |
| Xintela AB (publ) | 398 Thousand SEK | -509.296% |
| Ziccum AB (publ) | -4.18 Million SEK | 157.89% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 642.523% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 94.461% |
| CombiGene AB (publ) | -1.79 Million SEK | 234.797% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 89.917% |
| Intervacc AB (publ) | 10.48 Million SEK | 76.867% |
| Alligator Bioscience AB (publ) | 2.00 SEK | -121249900.0% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 133.983% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | -3.85 Million SEK | 162.873% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -242400.0% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 73.258% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 23.016% |
| Biovica International AB (publ) | 2.19 Million SEK | -10.277% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -242499900.0% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -246.429% |
| 2cureX AB (publ) | -1000.00 SEK | 242600.0% |
| I-Tech AB | 4.28 Million SEK | 43.341% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 75.235% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 149.199% |
| Nanologica AB (publ) | 2.97 Million SEK | 18.433% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 79.525% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 855.111% |
| Pila Pharma AB (publ) | 1.00 SEK | -242499900.0% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -135.895% |